TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A prospective study of 276 patients with HPV-positive oropharyngeal cancer found five-year locoregional control of 97% after a reduced-intensity radiation approach. The regimen lowered radiation to elective nodal areas and omitted selected low-risk regions; the authors say it still needs confirmation in a multicenter phase III trial.
A prospective study of 276 people with HPV-positive oropharyngeal cancer found strong five-year cancer control after treatment that reduced radiation to elective lymph-node regions, according to results published in JAMA Oncology. The findings add long-term evidence for a de-escalated approach, but researchers and an outside expert say a multicenter phase III trial is still needed before this specific regimen can be established as a standard.
Participants received definitive concurrent chemoradiation, with 30 Gy in 15 fractions delivered to treated nodal and subclinical regions, followed by a sequential boost of 40 Gy in 20 fractions. The approach also omitted selected low-risk nodal basins. Most patients received intensity-modulated radiotherapy; 20 received intensity-modulated proton therapy. The source report says patients received cisplatin-containing chemotherapy.
After a median follow-up of five years, 260 patients had no evidence of disease at five years, and 250 were alive at last follow-up. The reported five-year outcomes were 97.0% locoregional control, 90.8% overall survival, 91.2% distant metastasis-free survival and 85.9% progression-free survival. These measures describe different outcomes: control of cancer in the original region, survival, freedom from distant spread and freedom from progression, respectively.
The researchers reported no treatment failures in the nodal basins omitted from radiation. One elective nodal failure occurred in a contralateral lymph node that was indeterminate on baseline imaging and received 30 Gy. Most locoregional recurrences were in areas with known residual visible disease, according to the report. Distant-only recurrences occurred in 23 patients. At last follow-up, one patient was alive with disease.
Lower Nodal Doses, Long-Term Control
The results address a central trade-off in treating HPV-positive oropharyngeal cancer: maintaining cancer control while reducing radiation exposure to healthy tissue. Elective nodal irradiation treats lymph-node regions that may contain microscopic disease even when cancer is not visible. The study’s approach used a lower dose in those areas and excluded selected low-risk regions, while retaining concurrent chemotherapy and a higher-dose boost for targeted disease.
Reducing the volume and dose of radiation could limit exposure to structures involved in saliva production and swallowing. That matters because treatment effects can affect daily function and quality of life. However, this study does not establish that patients experienced fewer side effects: quality-of-life data were not reported in the long-term results described in the source. The authors also reported a low rate of gastrostomy tube insertion, but the supplied material does not give a specific rate for this cohort.
The findings are encouraging evidence for further testing, not proof that the approach is suitable for every patient. The study’s outcomes came from a particular treatment protocol and patient group, and the authors’ call for a randomized phase III trial reflects the need to compare it with standard treatment across multiple institutions.
Products Worth Considering
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
Philips Sonicare 6500 Series Rechargeable Electric Toothbrush with 2 Brush Heads, White
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
As an affiliate, we earn on qualifying purchases.
How the Reduced-Radiation Plan Worked
The report follows earlier results from the same research group. Nancy Y. Lee, MD, of Memorial Sloan Kettering Cancer Center, and colleagues had previously reported two-year outcomes that showed good locoregional control and survival, along with what they described as excellent quality of life. The new analysis was intended to assess whether those results remained durable over longer follow-up.
Outside expert David Sher, MD, of UT Southwestern Medical Center, said the study highlights that lowering the total dose to visible cancer is not the only way to reduce treatment intensity. Elective nodal radiation can expose normal tissue and nearby structures even when those areas do not contain known cancer. He also pointed to the use of PET-CT for all participants and MRI for most, as imaging may help clinicians identify lymph nodes that need higher doses.
Sher noted that the patients received cisplatin-containing chemotherapy and that HPV-associated oropharyngeal cancer is sensitive to cisplatin. He also said the report did not specify how many equivocal lymph nodes received a higher dose. Those details matter when interpreting outcomes and considering whether the results can be reproduced in other settings.
“The degree of success is remarkable given the extent of dose reduction.”
— David Sher, MD, of UT Southwestern Medical Center
Questions Before Wider Adoption
The study’s five-year findings do not settle whether the regimen performs as well as standard treatment in a direct comparison. The source describes a prospective study, but says a randomized, multicenter phase III trial is needed to confirm non-inferiority. The timing, design and availability of such a trial are not specified in the supplied material.
It is also unclear from the report how the outcomes compare across individual risk groups, how many indeterminate nodes received higher-dose treatment, and what quality-of-life outcomes were measured over the full follow-up period. The results should not be read as evidence that every patient with HPV-positive disease can safely receive less radiation; decisions depend on the disease pattern, imaging and treatment plan.
Phase III Testing Is the Next Step
The next major step is a randomized, multicenter phase III study comparing the reduced elective nodal radiation approach with an established treatment regimen. Such a trial could test whether cancer control remains comparable across institutions and clarify how patient selection, imaging and management of uncertain lymph nodes affect results.
Until that evidence is available, the current report provides long-term support for further evaluation rather than a change in standard care. Clinicians and patients will need to weigh the potential to reduce radiation exposure against the remaining uncertainty about comparative outcomes and long-term side effects.
Key Questions
What treatment approach was studied?
The study evaluated concurrent chemoradiation for HPV-positive oropharyngeal cancer with 30 Gy to elective nodal and subclinical regions, followed by a sequential boost. It also omitted selected low-risk nodal regions.
What were the five-year results?
The study reported 97.0% locoregional control, 90.8% overall survival, 91.2% distant metastasis-free survival and 85.9% progression-free survival at five years. These are separate measures and should not be treated as interchangeable.
Does the study show that reduced radiation is now standard care?
No. The results add long-term evidence, but the researchers and an outside expert said a randomized, multicenter phase III trial is needed to confirm the approach before it can be established as a standard.
Did the study show fewer treatment side effects?
The strategy was designed to reduce radiation exposure to normal tissue, including structures involved in swallowing and saliva production. However, the long-term report described in the source did not provide quality-of-life data, so it does not confirm the degree of any side-effect reduction.
Source: medpagetoday.com
